Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine as Rectal Protector in Prostate Cancer Radiotherapy
NCT00040365Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2002
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Percentage of Participants With a Good Toxicity Outcome Who Experienced an Acute Rectal Toxicity at 7 weeks. Started Jun 2002; status: completed.
02
Drugs
amifostine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00040365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040365.